Physician profile
William E Holder
NPI 1205178738
$5,265.50
in general payments reported to CMS, 2019-2025
33 companies · $1,448 in 2025
The $1,448 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,864 · 2022: $1,503 · 2023: $58.38 · 2024: $393 · 2025: $1,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938 · Travel and Lodging: $861 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.56 |
| Travel and Lodging | $861.16 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $861.16 | 2025 | |
| Abbvie INC. | $803.06 | 2021-2025 | |
| Biogen, INC. | $474.62 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $273.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $241.83 | 2021-2025 | |
| Genzyme Corporation | $233.16 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $222.23 | 2022 | |
| Amgen INC. | $182.95 | 2021-2025 | Uplizna |
| Amneal Pharmaceuticals LLC | $179.61 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $159.80 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $156.11 | 2024 | Opsumit, Uptravi |
| Allergan, INC. | $138.76 | 2021-2022 | |
| Lundbeck LLC | $117.84 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $117.48 | 2022-2024 | Ultomiris |
| Boston Scientific Corporation | $105.58 | 2021-2023 | Watchman Flx |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $105.25 | 2021-2023 | Freestyle Libre 2 |
| Ucb, INC. | $95.15 | 2021-2025 | Zilbrysq |
| Sk Life Science, INC. | $93.37 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $89.56 | 2021 | |
| Ani Pharmaceuticals, INC. | $87.22 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $82.07 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $80.54 | 2022-2025 | |
| Celgene Corporation | $65.98 | 2021-2022 | |
| Eisai INC. | $65.78 | 2025 | |
| Genentech USA, INC. | $53.09 | 2021-2025 | Xolair |
| Horizon Therapeutics Plc | $37.11 | 2022 | |
| Mallinckrodt Hospital Products INC. | $27.22 | 2024 | Acthar |
| Averitas Pharma INC. | $26.42 | 2025 | Qutenza |
| Upsher-Smith Laboratories LLC | $21.92 | 2021 | |
| Grifols USA, LLC | $20.63 | 2022 | |
| Tanabe Pharma America, INC. | $19.28 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.73 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Holder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.